Showing results (21-30 of 1,519) with videos related to

Sort By:
Pageof 152
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Quantifying and Communicating Uncertainty in Preclinical Human Dose-PredictionM Sundqvist, A Lundahl, M B Någård, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
A Population Approach to Characterize Interferon Beta-1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple SclerosisA Gulati, F Bagnato, P Villoslada, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Resistance Development: A Major Piece in the Jigsaw Puzzle of Tumor Size ModelingN Terranova, P Girard, U Klinkhardt, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Network-Based Analysis of Nutraceuticals in Human Hepatocellular Carcinomas Reveals Mechanisms of Chemopreventive ActionM Michailidou, I N Melas, D E Messinis, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 24, 2016
Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteersB T Gufford, J T Barr, V González-Pérez, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2016
Agent-Based Modeling in Systems PharmacologyJ Cosgrove, J Butler, K Alden, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2016
Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing RegimensC Stockmann, J S Barrett, J K Roberts, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2016
Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell CarcinomaA Ouerdani, H Struemper, A B Suttle, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 5, 2016
Weight-HbA1c-insulin-glucose model for describing disease progression of type 2 diabetesS Choy, M C Kjellsson, M O Karlsson, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 5, 2016
Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patientsM J E Brill, P A J Välitalo, A S Darwich, et al.
Pageof 152